XORTX Therapeutics Inc (XRTX)
3.050
-0.12
(-3.78%)
USD |
NASDAQ |
Apr 18, 16:00
XORTX Therapeutics Enterprise Value: 1.027M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 1.027M |
| April 17, 2024 | 1.267M |
| April 16, 2024 | 1.127M |
| April 15, 2024 | 1.367M |
| April 12, 2024 | 1.647M |
| April 11, 2024 | 2.036M |
| April 10, 2024 | 1.954M |
| April 09, 2024 | 2.546M |
| April 08, 2024 | 2.735M |
| April 05, 2024 | 2.326M |
| April 04, 2024 | 1.986M |
| April 03, 2024 | 1.427M |
| April 02, 2024 | 1.677M |
| April 01, 2024 | 2.206M |
| March 28, 2024 | 2.326M |
| March 27, 2024 | 2.126M |
| March 26, 2024 | 2.526M |
| March 25, 2024 | 2.576M |
| March 22, 2024 | 3.825M |
| March 21, 2024 | 4.598M |
| March 20, 2024 | 3.706M |
| March 19, 2024 | 4.825M |
| March 18, 2024 | 4.625M |
| March 15, 2024 | 5.265M |
| March 14, 2024 | 5.744M |
| Date | Value |
|---|---|
| March 13, 2024 | 4.845M |
| March 12, 2024 | 4.585M |
| March 11, 2024 | 3.825M |
| March 08, 2024 | 4.465M |
| March 07, 2024 | 4.145M |
| March 06, 2024 | 7.423M |
| March 05, 2024 | 4.525M |
| March 04, 2024 | 1.807M |
| March 01, 2024 | 1.475M |
| February 29, 2024 | 1.007M |
| February 28, 2024 | 1.597M |
| February 27, 2024 | 0.4055M |
| February 26, 2024 | 0.5074M |
| February 23, 2024 | -0.2521M |
| February 22, 2024 | 0.2876M |
| February 21, 2024 | -0.2121M |
| February 20, 2024 | 0.3275M |
| February 16, 2024 | -0.6119M |
| February 15, 2024 | -0.532M |
| February 14, 2024 | -0.6719M |
| February 13, 2024 | -0.492M |
| February 12, 2024 | -0.3721M |
| February 09, 2024 | -0.532M |
| February 08, 2024 | -0.432M |
| February 07, 2024 | -0.6699M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-2.310M
Minimum
Mar 28 2023
63.05M
Maximum
Sep 07 2021
9.238M
Average
7.024M
Median
Apr 17 2020
Enterprise Value Benchmarks
| ImmunoPrecise Antibodies Ltd | 28.28M |
| Acasti Pharma Inc | 3.742M |
| Aurinia Pharmaceuticals Inc | 345.12M |
| Edesa Biotech Inc | 9.561M |
| Lexaria Bioscience Corp | 23.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.333M |
| Total Expenses (Quarterly) | 1.393M |
| EPS Diluted (Quarterly) | -0.6699 |
| Earnings Yield | -118.6% |